Inactive Instrument

Serodus ASA Share Price

Equities

Duration

Period

Style

Serodus : Primary endpoint reached by SER150 Phase 2a study in Diabetic Nephropathy.	03/17/03	PU
Serodus : Q&A delisting from Oslo Axess	08/16/08	PU
Serodus : Extraordinary general meeting held	23/16/23	PU
Serodus : Viggo Harboe Holding 2006 ApS announces results of voluntary offer	23/16/23	PU
Serodus : Viggo Harboe Holding 2006 Aps Launces voluntary offer for outstanding shares in Serodus ASA – Acceptance period starting 31 October 2016	02/16/02	PU

Managers	Title	Age	Since
Arnstein Gunnestad Endresen CEO	Chief Executive Officer	71	01/16/01
Henrik Mordhorst DFI	Director of Finance/CFO	-	01/19/01

Members of the board	Title	Age	Since
Terri Sebree BRD	Director/Board Member	66	01/14/01
Viggo Gunnersen Harboe BRD	Director/Board Member	78	01/22/01
Søren Elmann Ingerslev CHM	Chairman	-	01/13/01

Sector

	1st Jan change	Capi.
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B